Key Points
- Director Johannes Gerardus Chri Schikan sold 7,000 shares on April 22 at $30.05 and 100 shares on April 23 at $30.03—about 7,100 shares totaling roughly $213,353—leaving him with 388,167 shares valued at approximately $11.66M, a ~1.77% reduction in his position.
- Multiple other insiders also sold during the same period—Anne Lesage sold 14,600 shares and Peng Lu sold 7,101 shares—indicating broader insider selling despite executives retaining significant holdings.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Johannes Gerardus Chri Schikan sold 7,000 shares of the company's stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $30.05, for a total value of $210,350.00. Following the transaction, the director directly owned 388,167 shares in the company, valued at approximately $11,664,418.35. This represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Johannes Gerardus Chri Schikan also recently made the following trade(s):
- On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
Pharvaris Stock Performance
NASDAQ PHVS opened at $28.63 on Friday. The stock has a fifty day moving average of $27.43 and a 200-day moving average of $25.84. The stock has a market capitalization of $1.87 billion, a P/E ratio of -8.50 and a beta of -2.58. Pharvaris N.V. has a 52 week low of $14.59 and a 52 week high of $30.24.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Equities research analysts forecast that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pharvaris
Several hedge funds have recently added to or reduced their stakes in PHVS. California State Teachers Retirement System boosted its holdings in Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company's stock worth $666,000 after buying an additional 520 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Pharvaris in the 4th quarter valued at approximately $35,000. Public Employees Retirement System of Ohio raised its position in shares of Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company's stock valued at $210,000 after acquiring an additional 1,300 shares during the period. Finally, Legal & General Group Plc boosted its stake in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on PHVS shares. Wedbush upped their target price on shares of Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a research report on Tuesday, April 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research report on Tuesday. Wall Street Zen downgraded shares of Pharvaris from a "sell" rating to a "strong sell" rating in a research note on Monday, April 13th. Citigroup restated a "buy" rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, Wolfe Research initiated coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an "outperform" rating and a $42.00 price objective on the stock. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.73.
Check Out Our Latest Stock Analysis on Pharvaris
Key Headlines Impacting Pharvaris
Here are the key news stories impacting Pharvaris this week:
- Negative Sentiment: Director Johannes Gerardus Chri Schikan sold a total of 7,100 shares across April 22 (7,000 shares at $30.05) and April 23 (100 shares at $30.03), representing a small (≈0.03–1.77%) reduction in his position while leaving him with a large remaining holding. Filing: Schikan SEC Filing
- Negative Sentiment: Insider Anne Lesage sold 14,600 shares (two blocks of 7,000 and 7,500 on April 22 at ~$30.05, plus 100 on April 23 at $30.03), reducing her stakes by single-digit to low-double-digit percentages but still retaining meaningful ownership. Filing: Lesage SEC Filing
- Negative Sentiment: Insider Peng Lu sold 7,101 shares (7,001 on April 22 at $30.05 and 100 on April 23 at $30.03), a roughly 9.6% reduction in their holding. Filing: Peng Lu SEC Filing
About Pharvaris
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
